OrbiMed
Braveheart Bio Launches with $185 Million Series A, Appoints Biogen CEO Christopher Viehbacher as Chair
Braveheart Bio; Series A financing; hypertrophic cardiomyopathy; Christopher Viehbacher; Biogen CEO; cardiovascular drug development; BHB-1893; myosin inhibitor; Andreessen Horowitz; Forbion; OrbiMed
Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise
royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment